SecSonar.com

Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Travere Therapeutics, Inc. (TVTX) is a Biotechnology company based in US with a market capitalization of $4.4B. Revenue grew 110.5% year-over-year and the company generated $37.8M in free cash flow. This page tracks TVTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 385 employees · IPO Nov 8, 2012

Valuation

Valuation & price

$42.59 · as of May 17, 2026 · -27.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

38.12

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$58.85$36.73$14.61Jul 25Dec 25Jul 26Jul 7, 25$14.61Jul 9, 25$16.33Jul 11, 25$16.47Jul 15, 25$16.38Jul 17, 25$16.51Jul 21, 25$15.82Jul 23, 25$16.13Jul 25, 25$15.32Jul 29, 25$15.53Jul 31, 25$15.45Aug 4, 25$15.96Aug 6, 25$17.24Aug 11, 25$17.28Aug 13, 25$18.05Aug 15, 25$18.82Aug 19, 25$17.63Aug 21, 25$17.79Aug 25, 25$17.23Aug 27, 25$17.44Aug 29, 25$17.50Sep 3, 25$19.61Sep 5, 25$21.64Sep 9, 25$21.64Sep 11, 25$25.00Sep 16, 25$22.77Sep 18, 25$24.19Sep 22, 25$25.43Sep 24, 25$24.41Sep 26, 25$25.30Sep 30, 25$23.90Oct 2, 25$24.22Oct 6, 25$26.13Oct 8, 25$26.20Oct 10, 25$25.16Oct 14, 25$26.14Oct 16, 25$27.51Oct 21, 25$27.80Oct 23, 25$28.15Oct 27, 25$29.77Oct 29, 25$29.98Oct 31, 25$35.16Nov 4, 25$34.13Nov 6, 25$33.30Nov 10, 25$34.38Nov 12, 25$36.47Nov 14, 25$34.50Nov 18, 25$36.00Nov 20, 25$34.73Nov 25, 25$36.01Nov 28, 25$35.41Dec 2, 25$33.99Dec 4, 25$35.33Dec 8, 25$34.29Dec 10, 25$34.38Dec 12, 25$34.83Dec 16, 25$35.85Dec 18, 25$34.49Dec 22, 25$36.50Dec 24, 25$40.28Dec 29, 25$38.88Jan 2, 26$39.52Jan 6, 26$35.80Jan 8, 26$35.60Jan 12, 26$34.10Jan 14, 26$28.93Jan 16, 26$27.87Jan 21, 26$28.25Jan 23, 26$29.44Jan 27, 26$30.03Jan 29, 26$31.99Feb 2, 26$33.10Feb 4, 26$31.68Feb 9, 26$30.07Feb 11, 26$30.22Feb 13, 26$27.82Feb 18, 26$27.87Feb 20, 26$30.39Feb 24, 26$30.88Feb 26, 26$29.72Mar 2, 26$29.53Mar 4, 26$28.18Mar 6, 26$27.24Mar 10, 26$28.63Mar 12, 26$27.55Mar 17, 26$27.76Mar 19, 26$27.72Mar 23, 26$27.75Mar 25, 26$27.56Mar 27, 26$27.25Mar 31, 26$29.71Apr 2, 26$30.44Apr 7, 26$31.67Apr 9, 26$31.44Apr 13, 26$30.70Apr 15, 26$40.95Apr 17, 26$40.77Apr 22, 26$40.09Apr 24, 26$40.50Apr 28, 26$40.89Apr 30, 26$42.12May 4, 26$44.91May 6, 26$44.76May 8, 26$42.60May 12, 26$42.84May 14, 26$44.10May 18, 26$42.89May 20, 26$43.49May 22, 26$44.43May 28, 26$47.76Jun 1, 26$45.04Jun 3, 26$45.20Jun 5, 26$45.81Jun 9, 26$48.57Jun 11, 26$48.91Jun 15, 26$53.80Jun 17, 26$54.14Jun 22, 26$55.11Jun 24, 26$57.69Jun 26, 26$58.85Jul 2, 26$56.92
$14.6152-week range$59.03
Loading valuation history…

Fundamentals

Key fundamentals

$4.4B

Market cap

110.5%

Revenue growth (YoY)

97.9%

Gross margin

$37.8M

Free cash flow (USD)

$5.9M

Net debt

13.1%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$133.6MFY 2017$154.9MFY 2018$164.2MFY 2019$175.3MFY 2020$198.3MFY 2021$131.8MFY 2022$109.5MFY 2023$145.2MFY 2024$233.2MFY 2025$490.7M
$133.6M$490.7M

Free cash flow by year

2016 → 2025

FY 2016$-13.5MFY 2017$-6.6MFY 2018$-44.7MFY 2019$-73.8MFY 2020$-162.6MFY 2021$-38.9MFY 2022$-214.7MFY 2023$-321.6MFY 2024$-338.7MFY 2025$37.8M
-$13.5M$37.8M

Gross margin by year

2021 → 2025

FY 202197.1%FY 202296.0%FY 202392.1%FY 202496.7%FY 202597.9%
97.1%97.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

22

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 4, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $225K · 10b5-1 PlanBaynes Roy D. · Director · $225KJun 16, 2026Filing
  • Insider sellInsider Sell $501K · 10b5-1 PlanCoughlin Timothy · Director · $500.7KJun 16, 2026Filing
  • 8-K eventExecutive Retirement AnnouncementJun 16, 2026Filing
  • 8-K eventLicense Agreement SignedJun 2, 2026Filing
  • 8-K eventEquity Incentive Plan UpdateMay 21, 2026Filing
  • Insider sellInsider Sell $141K · 10b5-1 PlanCoughlin Timothy · Director · $141.3KMay 19, 2026Filing
  • 8-K eventConvertible Notes IssuedMay 11, 2026Filing
  • Insider sellInsider Sell $115K · 10b5-1 PlanCline Christopher R. · CHIEF FINANCIAL OFFICER · $115.4KMay 6, 2026Filing
  • Insider sellInsider Sell $989K · 10b5-1 PlanDube Eric M · Director, CHIEF EXECUTIVE OFFICER · $988.9KMay 6, 2026Filing
  • Insider sellInsider Sell $101KHeerma Peter · CHIEF COMMERCIAL OFFICER · $101.4KMay 6, 2026Filing

Questions

Frequently asked questions

What is Travere Therapeutics, Inc.'s market cap?

Travere Therapeutics, Inc. (TVTX) has a market capitalization of $4.4B.

What is TVTX's P/E ratio?

A meaningful P/E ratio is not available for TVTX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is TVTX's price-to-book (P/B) ratio?

TVTX trades at 38.12 times book value per share.

Are insiders buying TVTX stock?

SEC Form 4 filings show no open-market insider buys at Travere Therapeutics, Inc. in the last 90 days (22 sells).

Same arena

Related companies in Biotechnology

SYRE

Spyre Therapeutics, Inc.

$4.4B

XENE

Xenon Pharmaceuticals Inc.

$4.3B

LGND

Ligand Pharmaceuticals Incorporated

$4.7B

CAI

Caris Life Sciences, Inc.

$4.7B

NAMS

NewAmsterdam Pharma Company N.V.

$3.9B

CPRX

Catalyst Pharmaceuticals, Inc.

$3.8B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.